| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f0544582d4ac84825b4f1b8ea7f8b7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e28d5faf4c724f170c9e704ca79899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a58de05b161f3d6360323abf78e12ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ad35a6f92b00eba0377911e613c8030 |
| publicationDate |
2022-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220088329-A |
| titleOfInvention |
The immunotherapeutic nanocage displaying PD-L1 binding peptide 2 and use in anti-cancer immunotherapeutic agent thereof |
| abstract |
The present invention relates to a ferritin nanocage fused with PD-L1 binding peptide 2 and its use as an anticancer immunotherapeutic agent, and the immune checkpoint receptor PD- L1-binding peptide 2 (PD-L1pep2: CVRARTR) was fused to human ferritin monomer to prepare a nanocage in which 24 PD-L1pep2 was displayed when the cage was formed. The nanocage of the present invention showed anticancer effect by effectively targeting colon cancer tissue, and when the anticancer drug doxorubicin was loaded inside the nanocage, it showed superior anticancer effect than the same amount of the PD-L1 antibody. Therefore, it is expected as a next-generation drug that overcomes the limitations of immune checkpoint blocking therapy using antibodies. |
| priorityDate |
2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |